Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 246
Tipo Título / Nombre Autor(es) Año
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C..., Bergua-Burgues JM 2024
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry Labrador J, Martínez-Cuadrón D, Boluda B, Serrano J, Gil C..., Bergua JM 2024
Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia Martin-Sánchez E, Blanco Fernández L, Kim PS, Bisht K, Wang H..., Bergua Burgues JM 2024
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry De la Torre EP, Serrano J, Martínez-Cuadrón D, Torres L, Sargas C..., Bergua JM 2024
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B..., Bergua JM 2024
Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry Martínez-Cuadrón D, Megías-Vericat JE, Gil C, Bernal T, Tormo M..., Bergua J 2024
Clinical Features and Treatment in Patients Diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema Epidemiologic Registry (EPI-BLAS study) Navarro Vicente I, Lloret Madrid P, Solana Altabella A..., Bergua Burgues JM 2023
LOTIS-5, an ongoing phase 3 randomized study of Loncastuximab Tesirine with Rituximab (Lonca-r) versus immunochemotherapy in patients with R/R DLBCL Carlo-Stella C, Kwiatek M, Chung M, Móciková H, Bergua-Burgues JM, Gao S, Grosicki S, Stathis A, Toupin D, Wang Y, Wang L, Hamadani M 2023
Incidence, risk factors and outcomes od second neoplasm in patients with acute promyelocytic leukemia: the PETHEMA -PALG experience Sobas M, Knopinska-Posluszny W, Pi?tkowska-Jakubas B..., Bergua Burgues JM 2023
AML-443 Clonal Evolution Analysis Using Next Generation Sequencing (NGS) Panel in a Cohort of 3,025 Patients With Acute Myeloid Leukemia (AML) Colmenares R, Sargas C..., Bergua Burgues JM 2023